Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

Recent analyst actions feature notable shifts in the technology and retail sectors, with Cloudflare (NET) and Target (TGT) receiving upgrades based on competitive positioning and potential acquisition ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain ...

Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent ...

Pfizer Inc (NYSE:PFE) maintains global operations across medicines and vaccines, delivering consistent earnings, operational ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 sales fade and key drugs lose exclusivity, putting near term growth firmly ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...